PPARgamma agonists in the treatment of type II diabetes: Is increased fatness commensurate with long-term efficacy?

International Journal of Obesity

Volumn 27, Issue 2, 2003, Pages 147-161

  Larsen, T M ^a   Toubro, S ^a   Astrup, A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Insulin resistance; Long term; Obesity; PPARgamma agonist; Thiazoledinediones

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; CIGLITAZONE; DARGLITAZONE; FARGLITAZAR; FATTY ACID DERIVATIVE; GW 0072; INSULIN; LG 100641; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PD 068235; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE; TZD 300512; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; BODY FAT; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; EDEMA; FATTY ACID BLOOD LEVEL; GENE MUTATION; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; LIVER TOXICITY; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SIDE EFFECT; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0037330414     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.802223     Document Type: Review

References (108)

1. Issemann I, Green S. Activation of a member of the steroid-hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-650.
2. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
3. Hansen JB et al. Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J Biol Chem 2001; 276: 3175-3182.
4. Peters JM et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2000; 20: 5119-5128.
5. Bastie C, Luquet S, Holst D, Jehl-Pietri C, Grimaldi PA. Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation. J Biol Chem 2000; 275: 38768-38773.
6. Leibowitz MD et al. Activation of PPAR delta alters lipid metabolism in db/db mice. FEBS Lett 2000; 473: 333-336.
7. Oliver Jr WR et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98: 5306-5311.
8. Ren DL, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS. PPAR gamma knockdown by engineered transcription factors: exogenous PPAR gamma 2 but not PPAR gamma 1 reactivates adipogenesis. Genes Develop 2002; 16: 27-32.
9. VidalPuig A et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996; 97: 2553-2561.
10. VidalPuig AJ et al. Peroxisome proliferator-activated receptor gene expression in human tissues - effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416-2422.
11. Auboeuf D et al. Tissue distribution and quantification of the expression of rnRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans - no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46: 1319-1327.
12. Mukherjee R, Jow L, Croston GE, Paterniti JR. Identification characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR gamma 2 versus PPAR gamma 1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997; 272: 8071-8076.
13. Kruszynska YT et al. Skeletal muscle peroxisome proliferator-activated receptor-gamma expression in obesity and non-insulin-dependent diabetes mellitus. J Clin Invest 1998; 101: 543-548.
14. Loviscach M et al. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia 2000; 43: 304-311.
15. Forman BM et al. 15-Deoxy-delta(12,14)-prostaglandin J(2) is a ligand for the adipocyte determination factor ppar-gamma. Cell 1995; 83: 803-812.
16. Kliewer SA et al. A prostaglandin J(2) metabolite binds peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation. Cell 1995; 83: 813-819.
17. Kliewer SA et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997; 94: 4318-4323.
18. Nagy L, Tontonoz P, Alvarez JGA, Chen HW, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma. Cell 1998; 93: 229-240.
19. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
20. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341-367.
21. Ibrahimi A et al. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol 1994; 46: 1070-1076.
22. Oberfield JL et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999; 96: 6102-6106.
23. Wright HM et al. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 2000; 275: 1873-1877.
24. Camp HS, Chaudhry A, Leff T. A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Endocrinology 2001; 142: 3207-3213.
25. Mukherjee R et al. A selective peroxisome proliferator-activated receptor-gamma (PPAR gamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocr 2000; 14: 1425-1433.
26. Morrison RF, Farmer SR. Role of PPAR gamma in regulating a cascade expression of cyclin-dependent kinase inhibitors p18(INK4c), and p21(Waf1/Cip1), during adipogenesis. J Biol Chem 1999; 274: 17088-17097.
27. Morrison RF, Farmer SR. Hormonal signaling and transcriptional control of adipocyte differentiation. J Nutr 2000; 130: 3116S-3121S.
28. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci USA 1998; 95: 4333-4337.
29. Soukas A, Socci ND, Saatkamp BD, Novelli S, Friedman JM. Distinct transcriptional profiles of adipogenesis in vivo and in vitro. J Biol Chem 2001; 276: 34167-34174.
30. Takamura T, Nohara E, Nagai Y, Kobayashi K. Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPAR gamma mRNA expression in 3T3-L1 adipocytes. Eur J Pharmacol 2001; 422: 23-29.
31. Vernochet C et al. PPARgamma-dependent and PPARgamma-independent effects on the development of adipose cells from embryonic stem cells. FEBS Lett 2002; 510: 94-98.
32. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79: 1147-1156.
33. Hu E, Tontonoz P, Spiegelman BM. Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha. Proc Natl Acad Sci USA 1995; 92: 9856-9860.
34. Kubota N et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4: 597-609.
35. Barak Y et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4: 585-595.
36. Rosen ED et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4: 611-617.
37. Gurnell M et al. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J Biol Chem 2000; 275: 5754-5759.
38. Young PW et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 1998; 284: 751-759.
39. Werman A et al. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgammal and -2 isoforms and influence of insulin. J Biol Chem 1997; 272: 20230-20235.
40. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 1996; 274: 2100-2103.
41. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 1997; 272: 5128-5132.
42. Camp HS, Tafuri SR. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem 1997; 272: 10811-10816.
43. Yang W et al. Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors. J Biol Chem 2001; 276: 38341-38344.
44. Camp HS, Whitton AL, Tafuri SR, PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes. FEBS Lett 1999; 447: 186-190.
45. Hauser S et al. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 2000; 275: 18527-18533.
46. Lefebvre AM et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998; 47: 98-103.
47. Hotta K et al. Relationships of PPARgamma and PPARgamma2 mRNA levels to obesity, diabetes and hyperinsulinaemia in rhesus monkeys. Int J Obes Relat Metab Disord 1998; 22: 1000-1010.
48. Edvardsson U et al. Rosiglitazone (BRL49653) a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res 1999; 40: 1177-1184.
49. Memon RA et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 2000; 141: 4021-4031.
50. Park KS et al. PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subiects. Diabetes 1997; 46: 1230-1234.
51. Rieusset J et al. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes. Diabetes 1999; 48: 699-705.
52. Lapsys NM et al. Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor gamma expression in human skeletal muscle. J Clin Endocrinol Metab 2000; 85: 4293-4297.
53. Rousseau V et al. Developmental and nutritional changes of ob and PPAR gamma 2 gene expression in rat white adipose tissue. Biochem J 1997; 321(Pt 2); 451-456.
54. Ribot J, Rantala M, Kesaniemi YA, Palou A, Savolainen MJ. Weight loss reduces expression of SREBP1c/ADD1 and PPARgamma2 in adipose tissue of obese women. Pflugers Arch 2001; 441: 498-505.
55. Nisoli E et al. Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion. Diabetes 2000; 49: 319-324.
56. Zierath JR et al. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology 1998; 139: 5034-5041.
57. Hallakou S, Foufelle E Doare L, Kergoat M, Ferre P. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation. Diabetologia 1998; 41: 963-968.
58. Way JM et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001; 142: 1269-1277.
59. Jiang G et al. Potentiation of insulin signaling in tissues of zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes 2002; 51: 2412-2419.
60. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.
61. Yakubu-Madus FE, Stephens TW, Johnson WT. Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione. Diabetes Obes Metab 2000; 2: 155-163.
62. de Souza CJ et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50: 1863-1871.
63. Chao L et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidaemic, effect of thiazolidinediones. J Clin Invest 2000; 106: 1221-1228.
64. Yamauchi T et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001; 276: 41245-41254.
65. Pickavance LC, Buckingham RE, Wilding JP. Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. Diabetes Obes Metab 2001; 3: 171-180.
66. Pickavance LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JP. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol 1999; 128: 1570-1576.
67. Danforth Jr E. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet 2000; 26: 13.
68. Arioglu E et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133; 263-274.
69. Burant CF et al. Troglitazone action is independent of adipose tissue. J Clin Invest 1997; 100: 2900-2908.
70. Hallakou S et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46: 1393-1399.
71. Okuno A et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354-1361.
72. Miles PD, Barak Y, He W, Evans RM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 2000; 105: 287-292.
73. Deeb SS et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287.
74. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000; 268: 178-182.
75. Hara K et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun. 2000; 271: 212-216.
76. Altshuler D et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80.
77. Ek J et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among: glucose tolerant Caucasians. Diabetologia 2001; 44: 1170-1176.
78. Ek J et al. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999; 42: 892-895.
79. Beamer BA et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998; 47: 1806-1808.
80. Barroso I et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
81. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339: 953-959.
82. Schmitz OE, Brock B, Madsbad S, Beck-Nielsen H. [Thiazolidine-diones-a new class of oral antidiabetics]. Ugeskr Laeger 2001; 163: 6106-6111.
83. Zinman B. PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. Diabetes Obes Metab 2001; 3(Suppl 1): S34-S43.
84. Unger RH, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 2001; 15: 312-321.
85. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARgammal gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001; 35: 17-23.
86. Camp HS et al. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 2000; 49: 539-547.
87. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000; 22: 1151-1168.
88. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517-523.
89. Belcher G, Matthews DR. Safety and tolerability of pioglitazone. Exper Clin Endocr Diabetes 2000; 108: S267-S273.
90. Shimizu H et al. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998; 21: 1470-1474.
91. Schwartz MW, Boyko EJ, Kahn SE, Ravussin E, Bogardus C. Reduced insulin secretion: an independent predictor of body weight gain. J Clin Endocrinol Metab 1995; 80: 1571-1576.
92. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-293.
93. Mori Y et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22: 908-912.
94. Kawai T et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 1999; 48: 1102-1107.
95. Miyazaki Y et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). Diabetes 2000; 49(Suppl 1): A299 (Ref Type: Abstract).
96. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23, 1067-1071.
97. Nakamura T et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation - double-blind placebo-controlled trial. Diabetes Res Clin Pract 2001; 54: 181-190.
98. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000; 49: 883-888.
99. Yanase T et al. Differential expression of PPAR gamma1 and gamma2 isoforms in human adipose tissue. Biochem Biophys Res Commun 1997; 233: 320-324.
100. Adams M et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153.
101. Sewter CP, Blows F, Vidal-Puig A, O'Rahilly S. Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. Diabetes 2002; 51: 718-723.
102. Hauner H, Wabitsch M, Pfeiffer EF. Differentiation of adipocyte precursor cells from obese and nonobese adult women and from different adipose tissue sites. Horm Metab Res Suppl 1988; 19: 35-39.
103. Miyazaki Y et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001; 44: 2210-2219.
104. Iwamoto Y et al. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19: 151-156.
105. Chilcott J, Tappenden P, Llyod Jones M, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001; 23: 1792-1823.
106. Frias JP, Yu JG, Kruszynska YT, Olefsky JM. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 2000; 23: 64-69.
107. Rocchi S et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001; 8: 737-747.
108. Shimaya A et al. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism 2000; 49: 411-417.